Exceptional 106-month survival in multiply relapsed small cell lung cancer after sequential anlotinib and short-course sintilimab: a case report. (PubMed, Front Oncol) - Sep 25, 2026 - "She achieved a partial response after concurrent chemoradiotherapy but developed recurrence in November 2018 and subsequently progressed after irinotecan-based and pemetrexed-based chemotherapy. However, because anlotinib had demonstrated activity before immunotherapy and was continued after sintilimab discontinuation, the relative contribution of each treatment cannot be determined. Further prospective studies with biomarker analyses are warranted."
IO biomarker • Journal • Endocrine Disorders • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
|
|
Jingwen Chen; Ping Gao; Ruzhu Wang; Tianshu Yang; Yishan Lu; Yuting Zhang
|